Pharmacology, Toxicology and Pharmaceutical Science
Antiparkinson Agent
13%
DOPA
100%
Dopamine
56%
Dopamine 1 Receptor
9%
Dopamine Receptor
22%
Dopamine Receptor Stimulating Agent
9%
Dystonia
68%
Glutamate Receptor
9%
Heteromer
9%
Hypokinesia
15%
Levodopa-Induced Dyskinesia
79%
Mouse Model
54%
Oxidopamine
13%
Parkinson's Disease
95%
Pharmacotherapy
15%
Receptor
72%
Receptor Agonist
20%
Receptor Subtype
9%
Replacement Therapy
20%
Rodent
9%
Systemic Administration
13%
Medicine and Dentistry
Association
13%
Bleeding
20%
Disease
20%
Female
13%
Hazard Ratio
6%
Lupus Erythematosus
6%
Observational Study
54%
Organ
54%
Patient
54%
Progressive Disease
6%
Proportional Hazards Model
6%
Rheumatology
20%
SLEDAI
6%
Systemic Lupus Erythematosus
54%
Neuroscience
Basal Ganglia
17%
Dyskinesia
7%
Dystonia
54%
L-DOPA
50%
Neuron
32%
Parkinson's Disease
69%
Striatum
30%